Abstract
Introduction
Experimental autoimmune encephalomyelitis (EAE) is a paralytic CNS disease that can be readily induced in different species and strains of experimental animals. The disease has been studied extensively in Lewis rats, which are highly susceptible to EAE induced by immunization with guinea pig spinal cord homogenate (gp-SCH), myelin basic protein (MBP) or proteolipid protein (PLP) emulsified in complete Freund's adjuvant (CFA). The dominant encephalitogenic epitope of MBP in the Lewis rat has been localized to residues 63-88 (1) and 68-86 (2, 3) . MBP 68-86-induced Lewis rat EAE is mediated by CD4 ϩ T lymphocytes, which predominantly express TCR V β 8.2 gene products and are MHC class II I-A restricted (4, 5) . A second MBP epitope that is encephalitogenic for Lewis rats has been localized to residues 87-99. This is a minor epitope since EAE can be induced only after administration of relatively high doses (6) (7) (8) . MBP 87-99 is I-E restricted in Lewis rats (6) and TCR usage is heterogeneous (7), but V β 6 predominates in T cell clones derived from spinal cords of paralyzed rats (9) . MBP 87-99 approximates the encephalitogenic sequence of MBP that induces EAE in SJL/J mice (i.e. residues 89-101) (10) and the residues 84-106 of the MBP molecule to which T cells from multiple sclerosis patients frequently respond (11, 12) .
Antigen-specific peripheral tolerance represents perhaps the most selective means for inhibiting encephalitogenic T cells. Suppression of EAE has been achieved by injection of large doses of myelin antigens i.v. (13) (14) (15) or intrathymically (16, 17) in soluble form; intracutaneously (18) or i.p. (19) with incomplete Freund's adjuvant (IFA); or by i.v. injection of syngeneic splenic antigen-presenting cells that have been pulsed with myelin antigen and chemically cross-linked using ethyl-carbodiimide (20) (21) (22) ; or by oral tolerance induction (reviewed in [23] [24] [25] .
An additional tolerogenic approach of increasing interest is nasal antigen administration (26, 27) . Several groups have now reported that nasal administration of autoantigens or peptides of self or foreign antigens can induce peripheral T cell tolerance (28) (29) (30) (31) (32) (33) , thereby protecting animals from the induction of autoimmune diseases (34, (31) (32) (33) . The mechanisms by which nasal administration of soluble antigens suppress autoimmunity are poorly understood. A number of studies have suggested that nasal administration of soluble antigens can lead to peripheral tolerance by a process of immune deviation (34, 35) or induction of other regulatory mechanisms (36) (37) (38) (39) .
To further define the principles of nasal tolerance induction, we generated three different MBP peptides (MBP 68-86, 87-99 and 110-128) and evaluated whether nasal administration of these peptides confers protection of Lewis rat EAE. We found that nasal administration of the encephalitogenic MBP peptides 68-86 or 87-99 suppresses EAE. MBP 68-86 and 87-99 given together had synergistic effects in suppressing EAE, and reversed ongoing EAE. The protection of EAE demonstrated in the present experimental system is probably related to non-regulatory mechanisms.
Methods

MBP and MBP peptides
MBP was prepared from guinea pig spinal cord (40) . Purity of MBP was checked by SDS-PAGE. We synthesized three different gp-MBP peptides, based on the numbering system of the gp-MBP molecule, covering the amino acid residues 68-86 (YGSLPQKSQRSQDENPV), 87-99 (VHFFKNIVTPRTP) and 110-128 (GLSLSAPSTGAGGGLPGPG). MBP 110-128 have been proven encephalitogenic in strain 13 guinea pigs but not in Lewis rats (41) . The peptides were synthesized at the Department of Virology, Swedish Institute for Infectious Disease Control, Stockholm, Sweden. Amino acid analysis confirmed the correct product.
SCH
Freshly isolated spinal cords from inbred guinea pigs were homogenized with a minimal amount of saline, frozen at -70°C and lyophilized.
Induction of nasal tolerance
Female Lewis rats, locally bred, originally obtained from Harlan (Zeist, The Netherlands), weighing 150-180 g, were used in this study. Tolerogens used in this study included MBP 68-86, 87-99 and 110-128, and a mixture of peptides 68-86 ϩ 87-99. This peptide mixture was obtained by mixing these two peptides at equal amount (1:1 by weight). All tolerogens were dissolved in PBS (0.05 M; pH 7.4) immediately before use. Groups of Lewis rats received the respective MBP peptides or PBS intranasally in a total volume of 60 µl each time with the use of a micropipette under light anesthesia with ether. The dosage and time schedule for nasal administration of each tolerogen is indicated in separate figures and figure legends.
Induction of EAE
EAE was induced by s.c. injection of inoculum containing 25 µg of gp-MBP, 4 mg of Mycobacterium tuberculosis (strain H37RA; Difco, Detroit, MI), 100 µl saline and 100 µl IFA (Difco). For induction of EAE with SCH, rats were immunized by s.c. injection of 50 mg of gp-SCH in CFA containing 2 mg M. tuberculosis (Difco) . Clinical scores were graded according to the following criteria: 0, asymptomatic; 1, flaccid tail; 2, loss of righting reflex with or without partial hind limb paralysis; 3, complete hind limb paralysis; 4, moribund; 5, dead. Clinical scores after onset of EAE were judged every day by at least two researchers. Body weight was examined daily.
Immunohistochemistry
Spinal cords from sacrificed animals were dissected and segments of the lumbar spinal cord were snap-frozen in liquid nitrogen. Cryostat sections (10 µm) were fixed in acetone at Ϫ20°C. Non-specific binding was blocked with normal horse serum (Vector, Burlingame, CA) for 30 min. Macrophage and T lymphocyte infiltrates were characterized in serial sections by incubation with 5 µg/ml of the mAb ED1 and W3/13 (Serotec, Oxford, UK) respectively. Biotinylated horse antimouse antibody (Vector) was used to couple the primary mAb with an avidin-biotin-peroxidase complex (Vector). After washing in PBS, substrate amino-ethyl carbazole was applied and incubated for 5 min. The slides were rinsed in tap water and mounted with Aquamount (Lerner, New Haven, CT). Controls included the omission of the primary and secondary antibody. Background staining was negligible.
Preparation of mononuclear cells (MNC) from draining lymph nodes
Rats were killed at day 12 p.i. The popliteal and inguinal lymph nodes (PILN) were removed, dissected and dispersed through a stainless steel wire mesh as described (42) . Cells were then washed 3 times in complete modified Eagle's medium (Flow, Irvine, UK) supplemented with 1% (v/v) minimum essential medium (Flow), 50 IU/ml penicillin, 60 µg/ ml streptomycin (Gibco, Paisley, UK), 2 mM glutamine (Flow) and 3% (v/v) heat-inactivated FCS (Gibco). PILN MNC were then adjusted to 2ϫ10 6 /ml.
Enumeration of MBP-and peptide-reactive IFN-γ-secreting cells by ELISPOT A solid-phase ELISPOT assay was used to enumerate PILN MNC secreting IFN-γ upon in vitro stimulation with MBP or MBP peptides (43) . Briefly, 96-well microtiter plates with nitrocellulose bottoms (Microtiter-HAM plates; Millipore, Bedford, UK) were coated with 100 µl aliquots per well of mouse monoclonal anti-rat IFN-γ antibody (Innogenetics, Gent, Belgium) at 15 µg/ml at 4°C overnight. After washing with PBS, 200 µl aliquots containing 4ϫ10 5 lymph node MNC were added to individual wells in triplicate, followed by adding antigen (MBP or MBP peptide) or mitogen [concanavalin A (Con A); Sigma, St Louis, MO] in 10 µl aliquots to a final concentration of 20 (MBP or MBP peptide) or 5 (Con A) µg/ml. After incubation at 37°C in 7% CO 2 and humidified atmosphere for 48 h, the wells were extensively washed. The plates were incubated with 100 µl of rabbit polyclonal antirat IFN-γ antibody (Innogenetics) diluted 1/2000 for 4 h at 20°C. After washing, the plates were incubated with biotinylated swine anti-rabbit IgG (Dakopatts, Copenhagen, Denmark) and with avidin-biotin-peroxidase complex (Vector) followed by peroxidase staining. The red-brown immunospots which corresponded to the cells that had secreted IFN-γ were counted in a dissection microscope. To calculate the numbers of T cells responding to a particular antigen or mitogen by IFN-γ secretion, numbers of spots in culture without antigen or mitogen added, which are considered as cells spontaneously secreting IFN-γ, were subtracted from values obtained after antigen or mitogen challenge. The data are expressed as numbers of spots per 10 5 cultured PILN MNC. The variation between triplicates was 10%.
Lymphocyte proliferation assays
For assessment of antigen-induced lymphocyte proliferation, a standard [ 3 H]thymidine incorporation test was used. Briefly, 200 µl aliquots of PILN MNC suspensions from EAE rats were set up in triplicates in round-bottomed 96-well polystyrene microtiter plates (Nunc, Copenhagen, Denmark) at a cell density of 2ϫ10 6 cells/ml in culture medium. Antigen or Con A was added to the same final concentrations as in the IFN-γ ELISPOT assay, unless otherwise indicated in figure legends.
After 60 h of incubation, the cells were pulsed with [methyl-3 H]thymidine (1 µCi/well; Amersham, Little Chalfont, UK) for another 12 h. Cells were harvested onto glass fibre filters (Titertek; Skatron, Lierbyen, Norway) and [ 3 H]thymidine incorporation was measured in a liquid β-scintillation counter.
Preparation of lymph node cells for in situ hybridization
Aliquots of 200 µl of pooled PILN MNC suspensions from each group of rats were plated in round-bottomed microtiter plates at a density of 2ϫ10 6 MNC/ml medium. Separate cultures received antigen (gp-MBP, 20 µg/ml) or mitogen (Con A, 5 µg/ml), or no antigen or mitogen. A culture time of 24 h was selected for evaluation of cytokine mRNA (43) . After washing in PBS, 10 5 MNC from each culture were dried onto restricted areas of ProbeOn slides (Fisher Scientific, Pittsburgh, PA) and stored in sealed boxes at -70°C.
In situ hybridization (ISH)
ISH was performed using 35 S-labeled synthetic oligonucleotide probes (Scandinavian Gene Synthesis, Kö ping, Sweden). For each cytokine (44), a mixture of four different 48 bp long oligonucleotide probes was used in order to increase the sensitivity of the method. The oligonucleotide sequences were obtained from GeneBank using the MacVector system. Control slides were hybridized with the same total amount of a sense probe with nucleotide sequence for exon 4 of rat IFN-γ. A constant ratio of the guanine/cytosine content of~60% was employed. The oligonucleotide probes were checked for absence of palindromes and long sequences of homology within the species against available GenBank data. The labeling was performed with [ 35 S]deoxyadenosine 5Ј-thiotriphosphate (New England Nuclear, Cambridge, MA) with terminal deoxynucleotidyl transferase (Amersham). After emulsion autoradiography, slides were coded and cells expressing numerous grains over their cytoplasm were counted by dark-field microscopy at ϫ20 magnification as previously described and validated (44, 37) . The results are expressed as numbers of labeled cells per 10 5 MNC. The control probe used in parallel with the cytokine probes on slides produced a uniformly weak background signal without revealing any positive cells. The number of cells used for ISH was not equal to the number that was ultimately detected on the slide. To compensate for cell losses, the total number of cells on the slides was regularly counted. With the help of a microscope grid used as a measuring unit, the radius (r) of the surface area (A) covered by cells was determined. The area A was calculated by the formula A ϭ πr 2 . Cells were usually counted in two grids at the periphery and one grid at the center of the surface covered by cells. In case of uneven distribution, cells in additional grids were counted. The mean value of the number of the cells per grid was determined and multiplied by A. The results were expressed as numbers of labeled cells per 10 5 MNC.
Adoptive transfer Donor rats received nasally MBP 68-86 ϩ 87-99 at a dose of 120 µg/rat on day -11, -10, -9, -8 and -7 relative to induction of EAE with gp-MBP ϩ CFA. Their spleens were removed 7 days after the last nasal administration and a single-cell suspension was prepared. Then 2ϫ10 7 spleen MNC were transferred i.p. to naïve syngeneic recipients that were immunized with gp-MBP ϩ CFA on the same day. The recipients were evaluated for EAE 11-18 days after immunization.
Statistics
Differences between pairs of groups were tested by Student's t-test. Differences between three or more groups were tested by one-factor ANOVA. The level of significance was set to α ϭ 0.05. All tests were two-sided.
Results
Nasal administration of encephalitogenic MBP peptides suppresses EAE in Lewis rats
To study whether nasal administration of defined MBP peptides could prevent EAE, Lewis rats received peptides MBP 68-86, 87-99 or 110-128 intranasally before induction of EAE. As shown in Fig. 1 , control rats receiving only PBS nasally and rats receiving MBP 110-128 nasally developed severe EAE, without differences between the two groups regarding mean maximal EAE score and mean accumulating EAE score. In contrast, rats receiving high-dose MBP 68-86 by the nasal route on day -11, -10, -9, -8 and -7 relative to immunization with gp-MBP exhibited only mild EAE. Amelioration of EAE was also observed in rats receiving MBP 87-99 nasally in terms of reduced mean accumulating score.
Rats receiving MBP 68-86 nasally showed partial tolerance to MBP 68-86 and to whole MBP as reflected by IFN-γ ELISPOT (Fig. 2) and T cell proliferation assays (mean Ϯ SEM of the proliferative response to MBP was 4005 Ϯ 406 in rats receiving MBP 68-86 versus 9170 Ϯ 820 in the PBStreated control rats, in the presence of similar background levels of 2174 Ϯ 483 versus 2790 Ϯ 127). Interestingly, nasal administration of MBP 68-86 nasally did not affect responses to MBP 87-99, and administration of MBP 87-99 only slightly affected the responses to MBP 87-99 and not to whole MBP as reflected by ELISPOT (Fig. 2) and T cell proliferation (data not shown). These results indicate that nasal administration of encephalitogenic MBP peptides only has the capacity of inducing antigen-specific T cell tolerance and subsequent amelioration of EAE. In this respect, MBP 68-86 is much more efficient in suppressing clinical EAE and inducing peptidespecific T cell suppression than MBP 87-99. Although MBP 68-86 and 87-99 are tolerogenic to gp-MBP induced EAE, MBP 68-86-induced disease was not affected by nasal MBP 87-99 pretreatment and vice versa (data not shown). 
Synergistic effects of MBP 68-86 and 87-99 in suppressing EAE
Despite the administration of relatively high doses of peptides prior to immunization, neither MBP 68-86 nor 87-99 completely prevented clinical EAE. With increasing dosage (300 µg/ratϫ5 times) of each peptide, complete prevention of EAE was still not achieved (data not shown). Therefore, we asked the question whether nasal administration of a mixture of these two encephalitogenic MBP peptides could prevent EAE. First, two groups of animals received either a mixture of MBP 68-86 ϩ 87-99 (1:1 in weight) or only MBP 110-128 on days -11, -10, -9, -8 and -7 relative to disease induction by immunization with gp-MBP ϩ CFA, at a dose of 120 µg/rat per administration. As shown in Fig. 3 , nasal administration of a mixture of MBP 68-86 ϩ 87-99 completely prevented EAE development. Examination of lambar spinal cord sections confirmed from control rats revealed extensive T cell and macrophage infiltrations in sections obtained on day 12 p.i., while no such cells were detected in sections of rats tolerized with peptide mixture (data not shown). Complete prevention of EAE was also achieved by reducing the total dose of peptide mixture. When rats received either MBP 68-86 ϩ 87-99 or MBP 110-128 at only three occasions, i.e. on day -9, -8 and -7 at a dose of 120 µg/rat per administration, no signs of EAE were observed in MBP 68-86 ϩ 87-99 pretreated rats, while rats receiving MBP 110-128 exhibited severe EAE (data not shown). Thus, MBP 68-86 and 87-99 synergize in preventing EAE.
We also evaluated the T cell responses on day 12 p.i. in rats receiving MBP 68-86 ϩ 87-99 nasally prior to immunization with gp-MBP ϩ CFA. As shown in Fig. 4(A) , proliferative responses to MBP were almost undetectable in MBP 68-86 ϩ 87-99-tolerized rats, while vigorous proliferative responses to MBP were detected in rats receiving MBP peptide 110-128. Similar proliferative response patterns were observed to MBP 68-86 ϩ 87-99 (Fig. 4B) , although they were somewhat lower. Numbers of MBP and MBP 68-86 ϩ 87-99-reactive IFN-γ-secreting cells were low in the MBP 68-86 ϩ 87-99- tolerized rats, while high numbers were recorded in rats receiving MBP 110-128 nasally. The two groups of rats showed similar levels of IFN-γ-secreting cells in response to purified protein derivative (PPD), indicating a highly antigenspecific suppression of T h 1-like responses in the MBP 68-86 ϩ 87-99-tolerized rats (Fig. 5) .
Antigen-driven cytokine mRNA expression in PILN MNC
To get further insight of the nature by which nasal administration of MBP 68-86 ϩ 87-99 suppresses EAE, PILN MNC separated on day 12 p.i. from rats tolerized with MBP 68-86 ϩ 87-99 and from rats receiving MBP 110-128 nasally. The PILN MNC were cultured in the presence and absence of MBP. Cells were then harvested and evaluated by ISH for frequencies of cells expressing cytokine mRNA. As shown in Fig. 6 , MBP 68-86 ϩ 87-99-tolerized rats had low numbers of MBP-reactive IFN-γ and tumor necrosis factor (TNF)-α mRNA expressing cells, while rats receiving MBP 110-128 Nasal administration of MBP 68-86 ϩ 87-99 does not prevent spinal cord-induced EAE We further tested whether nasal administration of MBP 68-86 ϩ 87-99 could prevent EAE induced by immunization with whole gp-SCH and CFA. Two groups of rats received either MBP 68-86 ϩ 87-99 or MBP 110-128 intranasally on day -11, -10, -9, -8 and -7, followed by induction of EAE with gp-SCH ϩ CFA. As shown in Fig. 7 , MBP 68-86 ϩ 87-99-tolerized rats showed a disease course of EAE that was only slightly delayed and shortened compared to the severe EAE seen in rats pretreated with MBP 110-128.
Spleen MNC from rats receiving MBP 68-86 ϩ 87-99 nasally do not transfer protection against EAE In order to determine whether nasal administration of MBP 68-86 ϩ 87-99 results in the generation of active suppression, we adopted a protocol described before (39) to transfer spleen MNC from MBP 68-86 ϩ 87-99-tolerized rats to naïve rats. All three rats adoptively transferred with spleen MNC from MBP 68-86 ϩ 87-99-tolerized rats developed EAE of a severity similar to untransferred control rats.
Nasal administration of MBP 68-86 ϩ 87-99 after T cell priming suppresses EAE To delineate whether nasal administration of MBP 68-86 ϩ 87-99 after T cell priming could suppress EAE, four groups of rats were immunized with gp-MBP ϩ CFA. Starting from 7 days p.i., rats received MBP 68-86 ϩ 87-99, MBP 110-128 or PBS nasally. As shown in Fig. 8(A) , rats treated with MBP 68-86 ϩ 87-99 at a dosage found to prevent EAE, showed some amelioration of EAE, but all rats developed EAE. Complete reversal of EAE was achieved only with high dose of MBP 68-86 ϩ 87-99. PBS-treated control rats and rats receiving MBP 110-128 nasally developed severe EAE. We also immunized another group of rats with gp-MBP ϩ CFA, and MBP 68-86 ϩ 87-99 or MBP 110-128 was administered . In rats receiving the higher dose (300 µg/ratϫ5 times) of MBP 68-86 ϩ 87-99 nasally, EAE was completely blocked. (B) Two additional groups of Lewis rats were immunized with gp-MBP ϩ CFA, followed by nasal administration of either MBP 110-128 (300 µg/ratϫ2 times) or MBP 68-86 ϩ 87-99 (300 µg/ratϫ2 times) on day 10 and 11 p.i., i.e. just before onset of clinical symptoms. Rats were monitored for the development of clinical EAE. MBP 68-86 ϩ87-99 completely blocked EAE, while MBP 110-128 had no effect.
at day 10 and 11 p.i., i.e. at two time points reflecting later priming. As shown in Fig. 8(B) , MBP 68-86 ϩ 87-99-treated rats showed no signs of EAE, whereas rats treated with MBP 110-128 developed severe EAE.
Discussion
We have documented that the sequences of the gp-MBP molecule which possess encephalitogenic activity in Lewis rats, i.e. residues 68-86 or 87-99, when administered by the nasal route, can confer tolerance to EAE and ameliorate the disease induced with gp-MBP ϩ CFA. For residue 110-128, no such tolerogenic or protective effects were detected. A hierarchy was observed regarding the protective effect of MBP 68-86 and 87-99, i.e. the protective effect of MBP 68-86 to gp-MBP-induced EAE is much stronger than that of MBP 87-99. This is consistent with the notion that MBP 68-86 represents the major encephalitogenic epitope, whereas MBP 87-99 is a minor epitope in Lewis rat EAE (45) . Our data thus indicate that only encephalitogenic MBP peptides can induce tolerance and that an antigen presentation event is necessary in inducing nasal tolerance.
Despite the relatively high dosage range of MBP peptides used, neither MBP 68-86 nor 87-99 conferred complete prevention to EAE induced with gp-MBP ϩ CFA. This indicates that none of these two peptides, when administered individually via the nasal route, can abrogate all encephalitogenic activity of gp-MBP. In contrast, a mixture of these two peptides prevented gp-MBP induced EAE completely, even when administered at lower doses. MBP 68-86 and 87-99 thus have synergistic effects in inducing tolerance to whole gp-MBP and in preventing EAE.
In line with previous studies (37, 38) , we demonstrate that tolerance can be induced by nasal administration of as little as 600 µg/rat of MBP 68-86, whereas in a previous study (46) using the same peptide for induction of oral tolerance, a minimum of 5 mg/rat was required. Major merits of tolerance induction by the nasal route are thus the saving of antigen besides being more effective (31, 39) .
The cellular mechanisms that are responsible for the induction of mucosal tolerance have been best described for oral tolerance, where feeding high doses of antigen can result in clonal deletion or anergy (46) (47) (48) (49) (50) , while oral tolerance induced by feeding low doses of protein is thought to be mediated by active suppression by regulatory T cells (49, 51, 52) . It is unclear whether similar mechanisms are activated within the respiratory tract. A number of studies have suggested that nasal administration of soluble antigens can lead to peripheral tolerance by a process of immune deviation (34, 35) or induction of other regulatory mechanisms (36) (37) (38) (39) . Evidence does not support active suppression as a mechanism in the present experimental system. First, the existence of immunoregulatory cells in vivo inducing so-called 'linked suppression' has been proposed (27) , i.e. treatment of animals with a peptide containing a single epitope can lead to inhibition of T cell responses to all epitopes on an antigen. In the present study, however, we found that T cell responses to MBP 87-99 were not affected in rats tolerized with MBP 68-86 (Fig. 2) and vice versa. Thus, there is no evidence for 'linked suppression' in our current experimental system. Furthermore, pretreatment of rats with MBP 68-86 or 87-99 did not affect MBP 87-99 or 68-86 induced disease. Second, evaluation of antigendriven cytokine mRNA expression in PILN MNC revealed that not only were numbers of MBP-reactive IFN-γ and TNF-α but also of TGF-β and IL-4 mRNA expressing cells low in MBP 68-86 ϩ 87-99-tolerized rats. Third, Metzler and Wraith (31) have shown that treatment of EAE in the H-2 u mouse with the peptide Ac 1-9 blocked EAE induced with SCH, a heterogenous mixture of potential autoantigens, each bearing a number of dominant, subdominant and cryptic determinants. In the present study, Lewis rats tolerized with MBP 68-86 ϩ 87-99 and immunized with gp-SCH ϩ CFA, developed similarly severe EAE compared as rats tolerized with the nonencephalitogenic peptide 110-128, although the EAE course was delayed and shortened (Fig. 7) . Finally, adoptive transfer studies indicate that cells from MBP 68-86 ϩ 87-99-tolerized rats do not transfer protection to EAE. Taken together, our results indicate that the T cell tolerance induced by nasal administration of MBP 68-86 ϩ 87-99 is more likely mediated by non-regulatory mechanisms, i.e. by T cell anergy or deletion.
Another study (39) showed that gp-MBP given as an aerosol to Lewis rats prior to and after immunization with gp-MBP ϩ CFA blocked EAE by generation of regulatory cells, and protection could be transferred with splenic T cells from aerosolized animals. In the present study, using encephalitogenic MBP peptides nasally, we failed to induce regulatory cells. Since it is difficult to estimate the amount of MBP delivered to the whole respiratory tract by aerosol, it is also difficult to document whether dose differences are responsible for the activation of different protective mechanisms. However, one previous study of oral tolerance (53) showed that epitopes of MBP that trigger TGF-β release after oral tolerization and mediate epitope-driven bystander suppression are distinct from encephalitogenic epitopes. It is not known whether MBP in aerosol form is preferentially processed into T cell epitopes (suppressor epitopes) that trigger TGF-β release in the respiratory tract mucosal tissues.
It is likely that nasal tolerance would be more difficult to achieve after T cell priming. When using MBP 68-86 ϩ 87-99 to treat ongoing EAE, we found that the dose schedule used for prevention of EAE failed to completely suppress ongoing EAE. Previous studies (54) (55) (56) indicate that the frequency of reactive T cells versus the amount of antigen could be an important parameter in the induction of certain forms of tolerance. Thus, one possibility to induce tolerance in established disease is to increase the amount of tolerogen. After doing so, we observed that ongoing EAE was completely blocked (Fig. 8A) . Previous studies (reviewed in 25) also indicate that timing and dose are critical in establishing oral tolerance. In our current nasal tolerance study, we found that the tolerogen concentration per dose is more important than the total dose, since nasal administration of two doses of MBP 68-86 ϩ 87-99 (300 µg/ratϫ2 times, total dose 600 µg/ rat) at later priming (day 10 and 11 p.i.) completely blocked EAE (Fig. 8B) , while nasal administration of a same total dose (600 µg/rat), but administered at five occasions at early priming, failed to completely block EAE (Fig. 8A) .
The present results demonstrate that autoimmune disease can be inhibited by nasal administration of peptides instead of intact self proteins. Nasal administration of peptides should be considered as an additional route by which the mucosal immune system can be utilized for therapeutic intervention, considering the much smaller doses needed for effectiveness and the ease of administration. However, under complex circumstances where epitope spreading (reviewed in 57) has occurred or multiple epitopes are already present, our current data implicates that multiple epitopes may be required to suppress disease manifestations. Alternatively, distinct peptide epitopes may be used to stop ongoing autoimmune disease as long as it induces a non-specific anti-inflammatory response, as has been shown for IL-4 following administration of altered MBP peptides (58) or PLP peptides (59) 
